Risk Assessment of Hospitalized Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Infected Patients Using Laboratory Data and Immune Cell Morphologic Assessment.

Thane Kubik¹, Mary Hou², Tammie Traverse³, Mireille Lareau³, Veronika Jenei⁴, Lisa Oberding¹, Dylan R Pillai⁵, Mark Gillrie⁶, Deepa Suryanarayan⁷, Davinder Singh Sidhu¹, Maria Vergara-Lluri⁸, Megan O Nakashima⁹, Etienne Mahe¹⁰

¹From the Department of Pathology & Laboratory Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada (Kubik, Oberding, Sidhu).

²Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada (Hou).

³the Division of Hematology, Alberta Precision Laboratories, Calgary, Alberta, Canada (Traverse, Lareau).

⁴Scientific Affairs, Global Marketing, CellaVision, Lund, Sweden (Jenei).

⁵The Department of Pathology & Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada (Pillai).

⁶The Department of Microbiology, Immunology & Infectious Diseases, and Department of Medicine, Snyder Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada (Gillrie).

⁷The Department of Internal Medicine Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada (Suryanarayan).

⁸The Department of Pathology and Laboratory Medicine, Keck School of Medicine, University of Southern California, Los Angeles (Vergara-Lluri).

⁹The Department of Laboratory Medicine, Cleveland Clinic, Cleveland, Ohio, (Nakashima).

¹⁰The Department of Pathology & Laboratory Medicine & Division of Hematology, Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada (Mahe).

PubMed DOI

Abstract

CONTEXT.—: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly infectious agent, with the propensity to cause severe illness. While vaccine uptake has been increasing in recent months, many regions remain at risk of significant coronavirus disease 19 (COVID-19)-related health care burden. Health systems will continue to benefit from the availability of a variety of clinica…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.